Core Insights - ARS Pharmaceuticals, Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York [1] - The company's management will engage in a fireside chat and one-on-one meetings with investors during the conference [2] Company Overview - ARS Pharmaceuticals is focused on empowering at-risk patients and their caregivers to manage allergic reactions that may lead to anaphylaxis [3] - The company is commercializing neffy® (EURneffy® in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, for patients aged 4 years and older in the U.S. and for various allergic reactions in the EU [3]

Core Viewpoint - Global Uranium Corp. has expanded its land position at the Airline Project in Wyoming, increasing its overall area to approximately 664 hectares, which supports the company's long-term exploration strategy [1][3][4]. Summary by Sections Land Expansion - The Airline Project originally consisted of a 60-hectare BLM claim block and a 258-hectare Wyoming State Mineral Lease, forming the initial land position [2]. - The company has added three new claims: a 7-hectare expansion to the north, a 205-hectare expansion to the west, and a 134-hectare expansion to the east [3]. Strategic Importance - The expansion of the Airline Project is seen as a crucial step in strengthening the company's position in the Copper Mountain district, allowing for better evaluation of geological trends and advancement of exploration plans [4]. Company Overview - Global Uranium Corp. focuses on exploring and developing uranium assets primarily in North America, holding key projects in Saskatchewan and Wyoming [8].

Company Overview - Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States, with a history of significant international projects [3] - The company is expanding its core business into the offshore energy industry [3] - Great Lakes operates the largest and most diverse fleet in the U.S. dredging industry, consisting of approximately 200 specialized vessels [3] - The company has a disciplined training program for engineers to ensure experienced-based performance [3] - Great Lakes has an Incident-and Injury-Free® (IIF®) safety management program integrated into its culture, emphasizing employee safety [3] Upcoming Event - Scott Kornblau, Senior Vice President and Chief Financial Officer, will present at NobleCon21 on December 3 at 12:00 PM Eastern Standard Time [1] - A high-definition video webcast of the presentation will be available the following day on the company's website and other platforms [2]

Core Insights - Enlivex has implemented the world's first RAIN prediction markets token digital asset treasury strategy through RAIN token accumulation [1][3][7] - The company is focused on the clinical development of Allocetra, a novel therapy for knee osteoarthritis, addressing a significant unmet medical need in a growing market [2][8] Company Developments - Enlivex has closed a $212 million private investment, with plans to utilize the proceeds for the RAIN prediction markets token treasury strategy while maintaining its core business operations [3][7] - Former Italian Prime Minister Matteo Renzi has joined the Board of Directors, emphasizing the importance of responsible innovation and the potential of blockchain technologies [5] RAIN Protocol Overview - RAIN is a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade custom options on various markets [4] - The protocol features a deflationary Buyback & Burn mechanism and aims to be a leading platform for prediction markets, promoting transparency and community participation [4] Market Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million people globally, with a projected increase to 78 million Americans by 2040 [8] - There are currently no FDA or EMA approved medications that can effectively halt or reverse the progression of joint damage in osteoarthritis patients, highlighting a critical need for effective treatments [8]

Core Viewpoint - Adial Pharmaceuticals has entered into a warrant inducement agreement with an institutional investor for the immediate exercise of existing warrants, aiming to raise approximately $2.86 million for working capital and corporate purposes [1][3]. Group 1: Warrant Inducement Agreement - The agreement involves the immediate exercise of Series C-1 Warrants to purchase up to 4,025,000 shares and Series E Warrants to purchase up to 5,190,675 shares at a reduced exercise price of $0.31 [1]. - The investor will receive new unregistered Series F Warrants to purchase up to 13,823,512 shares, with the same exercise price of $0.31, which will be exercisable upon shareholder approval [3]. - The closing of this transaction is expected around December 1, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and other general corporate purposes [1]. Group 3: Company Overview - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting Alcohol Use Disorder (AUD) [6]. - AD04 has shown promising results in reducing heavy drinking in patients during the ONWARD™ pivotal Phase 3 clinical trial, with no significant safety concerns reported [6]. - The company believes AD04 may also have potential applications for treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [6].

Core Points - Upexi, Inc. has entered into a securities purchase agreement with an institutional investor for the sale of 3,289,474 shares of common stock and warrants to purchase an equal number of shares at a combined purchase price of $3.04, which is a 1.3x premium to the Company's NAV [1][2] - The offering is expected to close around December 1, 2025, with gross proceeds of approximately $10 million and potential additional proceeds of up to $13 million from the exercise of the warrants [2] - The funds will be used for working capital, general corporate purposes, and a strategy focused on maximizing returns from Solana (SOL) [2][6] Company Overview - Upexi, Inc. is a digital asset treasury company focused on acquiring and holding Solana (SOL) while also being involved in the development, manufacturing, and distribution of consumer products [6] - The company currently holds over two million SOL and employs strategies such as intelligent capital issuance, staking, and discounted locked token purchases to enhance value [6]

Core Viewpoint - Vera Bradley, Inc. is set to report its third-quarter financial results for fiscal year 2026 on December 11, 2025, at 8:00 a.m. Eastern Time [1] Company Overview - Vera Bradley, based in Fort Wayne, Indiana, is a prominent designer of women's handbags, luggage, travel items, fashion and home accessories, and unique gifts, founded in 1982 by Barbara Bradley Baekgaard and Patricia R. Miller [3] - The brand is recognized for its innovative designs, iconic patterns, and vibrant colors that resonate with women globally [3] Business Segments - The company operates through two reportable segments: Vera Bradley Direct ("VB Direct") and Vera Bradley Indirect ("VB Indirect") [4] - VB Direct includes sales through Vera Bradley Full-Line and Outlet stores in the U.S., the company's websites, and the annual outlet sale in Fort Wayne [4] - VB Indirect encompasses sales to approximately 1,100 specialty retail locations, select department stores, national accounts, third-party e-commerce sites, and royalties from licensing agreements [4]

Core Insights - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [3] Company Participation - Thomas Zindrick, President, CEO, and Chairman of the Board, along with Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 12:00 p.m. ET in New York, NY [1] Clinical Trials - Olvi-Vec, the company's lead product, is currently being evaluated in two U.S.-based clinical trials: - OnPrime/GOG-3076, a Phase 3 trial for platinum-resistant/refractory ovarian cancer [3] - VIRO-25, a Phase 2 trial for non-small-cell lung cancer [3] - Additionally, Olvi-Vec is being evaluated in a China-based Phase 1b trial for recurrent small-cell lung cancer [3] Proprietary Technology - The core of Genelux's discovery and development efforts is its proprietary CHOICE™ platform, which has led to the development of an extensive library of oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec [3]

Core Insights - VCI Global Limited has acquired approximately 4 million additional OOB tokens as part of its US$50 million secondary-market purchase program, enhancing its total holdings to approximately 254.2 million tokens, making it the largest single token holder in the OOB ecosystem [1][2] - The acquisition reflects VCI Global's confidence in the growing stablecoin-driven payments landscape and the strategic importance of the Oobit ecosystem, which connects USDT and future stable assets to real-world merchant acceptance [2][3] - The OOB token is positioned for long-term appreciation, supported by the increasing global use of USDT, which has surpassed US$12 trillion in annual settlement, indicating a strong market for stablecoin transactions [4][6] Company Strategy - VCI Global's structured treasury-accumulation strategy aims to progressively reduce circulating supply and enhance institutional liquidity depth, laying the groundwork for potential asymmetric upside [5] - The company is focused on building a strategically aligned digital-asset treasury, with a commitment to integrating technology innovation within financial ecosystems to capture opportunities in the evolving digital economy [8] Market Context - The rapid global adoption of Tether's USDT has established it as the dominant digital settlement currency, with Oobit serving as a gateway for stablecoin spending and merchant acceptance [3][4] - The transaction volume of USDT in 2023 has exceeded US$12 trillion, surpassing traditional payment networks like Visa and Mastercard, highlighting the growing significance of stablecoins in the financial landscape [8]

Core Insights - The financial statement for Havila Finans AS for the third quarter of 2025 has been released, providing insights into the company's performance during this period [1][2] Financial Performance - The financial results for Q3 2025 are detailed in the attached document, which includes key metrics and figures relevant to the company's operations [1] - The Chief Financial Officer, Arne Johan Dale, is available for contact regarding the financial statement, indicating a level of transparency and accessibility for stakeholders [2]